You are here
The Dr. Charles I. Jarowski Industrial Pharmacy Symposium
Tenth Annual Dr. Charles I. Jarowski Industrial Pharmacy Symposium
Monday, June 4, 2018
D’Angelo Center, Room 416
St. John's University, Queens, NY
For additional information, please contact:
Diana J Patino-Castro
St.Albert Hall, 171
About the Symposium
In 2006, three distinguished Pharmacy professionals proposed that they create an alumni group to build support for St. John’s College of Pharmacy and Health Sciences and its Industrial Pharmacy Program. With the goal of inspiring and training the next generation of research scientists, Salah Ahmed ’85GP, ’91Ph.D., Navnit Shah ’73GP, ’81Ph.D. and Abu Serajuddin ’82Ph.D. formed the Industrial Pharmacy Committee.
Together they conceptualized the Dr. Charles I. Jarowski Industrial Pharmacy Symposium, which would act as a dynamic forum for the exchange of information among distinguished research scientists. The Symposium would be an annual event designed to offer our world class alumni the opportunity to explore topics relevant to the changing dynamics within the pharmaceutical industry. It would also act as an opportunity for networking and professional development between students, alumni and industry representatives.
Mansoor Khan, R.Ph. ’92Ph.D. was the first of many distinguished alumni to present at the Jarowski Symposium. He would subsequently become a key member of the Industrial Pharmacy Planning Committee.
Today, the Symposium has evolved into a major event for both the University and distinguished scientists in Pharmacy and the related professions, attracting over 100 participants annually. The theme for the Symposium is chosen by the Industrial Pharmacy Planning Committee each year to reflect the current trends in the pharmaceutical industry.
Each year, selected graduate students in the Industrial Pharmacy Program have the honor of presenting their research findings to attendees, affording them the opportunity to develop their presentation skills, seek career guidance and engage in networking with their peers and world class scientists.
Pharmaceutical industry suppliers and manufacturers also have the opportunity to sponsor the Symposium. In recognition of their support, they are given the chance to set up tables to demonstrate their products and showcase their technology to their key customers, our alumni.
Since its inception, the Dr. Charles I. Jarowski Symposium has become one of the largest academic forums for Industrial Pharmacy in the Northeast.
Read about the Seventh Annual Dr. Charles I. Jarowski Industrial Pharmacy Symposium that was held on Wednesday, June 19, 2013.
7:45 a.m.–8:15 a.m.
Registration and breakfast
D’Angelo Center Lobby
8:30 a.m.–9:15 a.m.
College of Pharmacy and Health Sciences Keynote Address
D’Angelo Center Ballroom
Speaker: Dipen Desai, Ph.D., MBA, Senior Director, Formulation Research & Design, Kashiv Pharma
9:30 a.m.–10 a.m.
Coffee break and Exposition
10:00 a.m.–11:30 a.m.
Session 1–Regulatory Landscape
Sid Bhoopathy, Ph.D.,Chief Operating Officer, Absorption Systems
Seyoum Ayehunie, Ph.D., Vice President of Immunological Systems, MatTek Corporation
11:30 a.m.–1:00 p.m.
D’Angelo Center, Room 128
Speaker: Omid Farokhzad, M.D., Professor, Harvard Medical School
1:15 p.m.–2:45 p.m.
Session 2–Drug Delivery Technology
D’Angelo Center, Room 206
Moderator: Vivek Gupta, Ph.D., Assistant Professor, Department of Pharmaceutical Sciences
Bozena B. Michniak-Kohn, Ph.D., Professor, Department of Pharmaceutics, Rutgers University
Ram Mahato, Ph.D., Professor and Chair, Department of Pharmaceutical Sciences, University of Nebraska Medical Center
Matthew Burke, Ph.D., Head of Drug Delivery, Pharmaceutical Development, GlaxoSmithKline (GSK)
3:00 p.m.–4:30 p.m.
Moderator: Senshang Lin, Ph.D., Professor, Department of Pharmaceutical Sciences
William Elmquist, Ph.D., Pharm.D., Distinguished Professor, Department of Pharmaceutics, University of Minnesota
Fatemeh Akhlaghi, Ph.D., Pharm.D., Professor and Chair, Department of Pharmaceutics, University of Rhode Island
Guoying Tai, Ph.D., US In Vitro Metabolism, GlaxoSmithKline (GSK)
4:30 p.m.–5:30 p.m.
Poster viewing/exposition and open reception
5:30 p.m.–6:00 p.m.
Awards and closing remarks
Fatemeh Akhlaghi, Ph.D., Pharm.D., is Professor of Pharmacokinetics and the Ernest Mario Distinguished Chair of Pharmaceutics in the College of Pharmacy, University of Rhode Island (URI). She has more than 20 years of experience in clinical pharmacology research and extensive history of clinical collaboration with academia and pharmaceutical industry. She has obtained a Pharm.D. from the Ferdowsi University of Mashhad in Iran and a Ph.D. from the University of Sydney, Australia. Consequently, she has completed a postdoctoral fellowship at the University of Sydney and another post doc at the University of Cambridge, United Kingdom, before joining URI in 2001. Her laboratory specializes in investigating the effect of diabetes and fatty liver disease on the expression and activity of drug metabolizing enzymes and transporters. Another research area pursued is supporting the National Institute of Alcohol Abuse and Addiction in development of novel compounds for treatment of alcohol used disorder. Her mass spectrometry based laboratory specializes in drug metabolism and transporter studies and utilizing semimechanistic pharmacokinetics and pharmacodynamics (PKPD) modeling in preclinical or clinical drug development. Currently, Dr. Akhlaghi supervises six Ph.D. and one master’s student and since 2001, her laboratory graduated nine PhDs, six master’s, and seven postdoctoral research associates.
Seyoum Ayehunie, Ph.D., is Vice President of Immunological Systems at MatTek Corporation in Ashland, MA. Dr Ayehunie received his Ph.D. in Medical Microbiology at the Karolinska Institute in Stockholm, Sweden, in 1992 and did his postdoctoral fellowship at Dana-Farber Cancer Institute, Harvard Medical School, in Boston, MA, from 1993 to 1997. At Harvard, Dr. Ayehunie was involved in HIV vaccine research and received the Fogarty International and NIH fellowship awards, and also worked as an instructor of medicine. In 1998, Dr. Ayehunie joined MatTek Corporation and his research has been focused on developing marketable 3D organotypic tissue models for screening pharmaceutical compounds and formulations for their safety and efficacy. He has received multiple Small Business Innovation Research grant awards from the National Institutes of Health and US Department of Defense, which led to the development of more than four commercial products. In the last four years, he developed a human small intestinal tissue model (EpiIntestinal™) that mimics the structure and physiology of the human intestine. The small intestinal tissue model has received positive feedback from major pharmaceutical drug companies involved in intestinal drug permeation and transport, drug-drug interaction, inflammation, drug toxicity, wound healing, and microbial invasion studies. He has also collaborated with numerous academic research institutions which have utilized these in vitro human organotypic tissue models. Dr. Ayehunie has more than 35 publications in refereed journals to his credit and has made a number of presentations on his work.
Matthew Burke, Ph.D., is Head of Drug Delivery in the Platform Technologies and Science Department at GlaxoSmithKline (GSK). He leads a group guiding the drug delivery strategy at GSK that includes internal development and external partnerships. Dr. Burke is a subject matter expert on oral modified release and continuous manufacturing and has worked at multiple sites in the US and UK within GSK. He has served as an adjunct professor at North Carolina State University in the Biomolecular and Chemical Engineering department and at the University of North Carolina in the Chapel Hill School of Pharmacy.
William F. Elmquist, Ph.D., Pharm.D. is currently Distinguished Professor and Director of the Brain Barriers Research Center, at the University of Minnesota, Department of Pharmaceutics. He received his pharmacy degree at the University of Florida, and Pharm.D. and Ph.D. (pharmacokinetics) from the University of Minnesota. His research has studied the influence of active efflux transporters in the blood-brain barrier (BBB) on CNS drug distribution. An important project currently underway is examining the determinants of anticancer drug permeability in the blood-brain barrier to improve the treatment of brain tumors. Long-term objectives of Dr. Elmquist's research include examining expression and regulation of transport systems in key tissues that influence drug disposition, and how variability in expression, either genetically or environmentally controlled, may contribute to variability in drug response in the patient. Dr. Elmquist has long been a consultant to the pharmaceutical industry and the NIH, served on many journal editorial boards, and is a Fellow of the American Association of Pharmaceutical Scientists (AAPS).
Omid Farokhzad, M.D., is a Professor at Harvard Medical School and a Physician-Scientist in the Department of Anesthesiology at Brigham and Women’s Hospital (BWH). Dr. Farokhzad established and directs the Center for Nanomedicine at BWH. He is a faculty member of the Brigham Research Institute Cancer Research Center and the Dana Farber/Harvard Cancer Center. Dr. Farokhzad and his team of scientists have developed a myriad of nanotechnologies for medical applications. He has authored more than 150 papers (>33,300 citations; H-Index 75) and is an inventor of more than 150 issued/pending patents worldwide.
The technologies that Dr. Farokhzad and colleagues have developed formed the basis for the launch of five biotechnology companies: BIND Therapeutics, Inc. (clinical stage public company acquired by Pfizer), Selecta Biosciences, Inc. (clinical stage public company), Tarveda Therapeutics (clinical stage private company), Placon Therapeutics (clinical stage private company), and Seer Biosciences (preclinical stage private company). These companies are translating the aforementioned academic innovations toward commercialization and societal impact. Dr. Farokhzad has served in various capacities on the Board of Directors and the Scientific Advisory Board of these companies.
He was a recipient of the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes, for the development and industrialization of nanoparticle technologies for medical applications. In 2014, he received the Golden Door Award from the International Institute of New England for his societal and economic impact as a naturalized US citizen. In 2015, he was named as one of “The Worldview 100” by Scientific American, which recognized visionaries who shape biotechnology around the world. In 2016, he was among the recipients of the Ellis Island Medal of Honor for his scientific, societal, and economic contributions to America as an immigrant.
Dr. Farokhzad was elected to the College of the Fellows of the American Institute for Medical and Biological Engineering. He was selected by Thomson Reuters among the “Highly Cited Researchers” in 2014, 2015, and 2016. The Boston Globe selected him among the top innovators in Massachusetts and the Boston Business Journal selected him among the “Health Care Champions” for his innovations. In 2012, he was among the regional Ernst & Young Entrepreneur Of The Year® awardees. He serves on numerous editorial boards and is the Associate Editor of ACS Nano.
Dr. Farokhzad completed his postgraduate clinical and postdoctoral research trainings, respectively, at the BWH/HMS and MIT in the laboratory of David H. Koch Institute Professor Robert S. Langer, Sc.D. He received his M.D. and M.A. from Boston University School of Medicine and his M.B.A. from the MIT Sloan School of Management.
Ram I. Mahato, Ph.D., is a Professor and Chairman of the Department of Pharmaceutical Sciences, University of Nebraska Medical Center. He was a professor at The University of Tennessee Health Science Center, Research Assistant Professor at the University of Utah, Senior Scientist at GeneMedicine, Inc., and a postdoctoral fellow at the University of Southern California in Los Angeles, CA; Washington University in St. Louis, MO; and Kyoto University, Japan. He received a Ph.D. in Drug Delivery from the University of Strathclyde, UK, and B.S. from China Pharmaceutical University, Nanjing. He has published 140 papers, 18 book chapters, holds two US patents, and has edited/written nine books and 11 journal issues (Google Citations= 8560 and h-Index =54). He is a CRS and AAPS Fellow. Dr. Mahato is applying sound principles in pharmaceutical sciences in the context of the latest advances in life and material sciences to solve challenging drug delivery problems in therapeutics. His research interests include delivery and targeting of small molecules, miRNA and genes using novel polymeric and lipid carriers for treating cancer (pancreatic, prostate, and melanoma), liver fibrosis, and diabetes.
Bozena B. Michniak-Kohn, Ph.D., is a tenured Professor of Pharmaceutics at the Ernest Mario School of Pharmacy, and Founder /Director of the Center for Dermal Research (CDR) at Rutgers, The State University of New Jersey, in Piscataway, NJ. Her main focus is topical, transdermal, and buccal drug delivery. Dr. Michniak-Kohn has more than 35 years of experience in design and optimization of topically applied formulations and transdermal patches. She holds patents for novel drug carrier approaches for dermatologicals. Dr. Michniak-Kohn received her B.Sc (Honors) in Pharmacy and Ph.D. in Pharmacology from the U.K. She has directed over 50 Ph.D. and master’s students and the work resulted in more than 120 peer-reviewed manuscripts, more than 420 abstracts, two books, and 35 book chapters. Dr. Michniak-Kohn is a member of 10 journal editorial boards, several scientific advisory boards, a member of the Board of Trustees at TRI Princeton, and is a reviewer for approximately 42 pharmaceutical and drug delivery journals. For this work she was awarded Fellow status of the American Association of Pharmaceutical Scientists (AAPS) in 2008.
Guoying Tai, Ph.D., obtained her Ph.D. from the University of Washington in Medicinal Chemistry with strong training on P450 enzymology and drug metabolism. She subsequently joined GlaxoSmithKline in 2006 and has worked in the preclinical Drug Metabolism and Pharmacokinetics department for nine years focused on mechanistic extrapolation of in vitro ADME data to predict and understand clinical drug interactions, disposition, and safety. Dr. Tai is currently leading a group at Investigative Safety and Drug Disposition in GlaxoSmithKline’s King of Prussia site, and her team is responsible for providing support on drug metabolism and disposition as well as drug-drug interaction risk assessment for drug development through candidate selection toward post marketing.
St. John’s University College of Pharmacy and Health Sciences calls for presentations at the 10th Annual Dr. Charles I. Jarowski Symposium on November 1, 2017, in Queens, NY. The theme of the symposium is “From Bench to Beside—Advances in Delivery Technologies and Regulatory Strategies for New Drug Approval.” Authors are encouraged to submit their presentation abstracts in line with the symposium theme as early as possible, but no later than 5 p.m. EDT, on Friday, October 6, 2017.
Abstract Guidelines and Submission
Abstract Submission Deadline–5 p.m. EDT, October 15, 2017
Abstracts must be submitted to firstname.lastname@example.org.
- Abstracts should have the following format:
a.Title of the abstract
b. Names of the Author(s) (First Name Last Name1(indicate presenting author with an asterisk), First Name Last Name2, etc.)
c. Affiliation (with address) of each author
d. Introduction and Purpose
e. Study Design and Methods
h. Acknowledgements and references (optional)
- Abstracts must be typed using Times New Roman font, Size 11, Line Spacing 1.5, with fixed overall margins of 0.75 inches on all four sides.
- Abstracts may contain up to 400 words. Use of data figures and tables is encouraged. Up to two figures/tables can be incorporated in the abstract body.
- The actual abstract must be no more than one printed page.
- Multiple abstracts from same author(s) will be considered.
- The abstract should be submitted by e-mail as an attachment in Microsoft Word (.doc/.docx) format only.
- Please specify during submission if you wish to be considered for a podium presentation.
- If selected for a podium presentation, guidelines will be sent out separately.
** The author responsible for correspondence must include his/her e-mail address and phone number for communication in the body of the e-mail.
Presentation of a poster provides an opportunity for effective one-to-one communication. The longer presentation time of the poster session enables the author(s) to present a more in-depth description and discussion of their work.
To make a successful poster presentation:
- The poster must be put up at least 30 minutes prior to the start of the poster session.
- The poster must correspond to the title and content of the abstract submitted.
- The poster must be designed to fit within the confines of a 48” x 36” poster board, and consist of materials that can be mounted easily with push pins.
- The poster must be in logical sequence, i.e., introduction, study design and methods, results, and conclusion.
- Posters should be designed for clear viewing from a distance of beyond 3 feet so that they can be viewed by a number of people at the same time.
- To ensure visual effectiveness of the poster, large lettering and a minimum of text should be used. Use of color can visually enhance the poster.
- The poster should be removed immediately at the close of the poster session.
- All posters will be allotted a number. On presentation day, the poster should be mounted onto the numbered poster board provided by the symposium.
- Presenting authors must be present at their posters during the entire session.
- Presenting authors will be responsible to set up and remove their posters.
New York LaGuardia Airport Marriott
102-05 Ditmars Boulevard, East Elmhurst, NY, 11369
The closest full-service hotel to the St. John’s University Queens campus, located adjacent to LaGuardia Airport and just minutes from Manhattan.
For an interactive brochure, Click Here
To reserve, Click Here
Courtyard by Marriott New York JFK Airport Hotel
145-11 N Conduit Ave, Jamaica, NY 11436
Located immediately adjacent to JFK International Airport. This Marriott location is conveniently near the St. John’s University Queens campus.
To Reserve, Click Here
The park-like Queens campus is readily accessible by car, bus, subway, or air. Located between JFK and LaGuardia Airports, the campus is just off the Grand Central Parkway, which connects Nassau and Suffolk Counties to Queens, Manhattan, and upstate New York.
St. John's University
8000 Utopia Parkway
Queens, NY 11439
GPS: 40.721378, -73.790375
Take the Queens Midtown Tunnel to the Long Island Expressway, exit at Utopia Parkway. Stay on the service road to Utopia Parkway and turn right. Follow Utopia Parkway to Union turnpike; the campus is on the right.
Take the Belt Parkway (East) to the Van Wyck Expressway (678 N.), exit at Main Street/Union Turnpike. Proceed to the third traffic light and make a right onto the Grand Central Parkway service road. Go left on Utopia Parkway (at fourth traffic light) and proceed to the campus.
Take the Jackie Robinson Parkway (East) to the Grand Central Parkway (East); exit at Utopia Parkway, and make a left on to the campus.
From the Bronx
Take the Throgs Neck Bridge to the Clearview Expressway. Take exit 2 and make a right onto Union Turnpike. Make a left onto Utopia Parkway; proceed to main gate (1) and make a right onto the campus.
Take the Triboro Bridge to the Grand Central Parkway. Exit at Utopia Parkway. Turn left at the light and left onto the campus.
From Long Island (North)
Take the Northern State Parkway to the Grand Central Parkway, exit at 188th Street. Turn left at the light, and make an immediate right onto the service road. Follow the service road to Utopia Parkway; bear right to campus.
Take the Long Island Expressway and exit at Utopia Parkway. Make a left on Utopia Parkway and proceed to Union Turnpike. The campus is on the right.
From Long Island (South)
Take the Southern State Parkway to the Cross Island Parkway. Proceed to the Grand Central Parkway (west), and exit at 188th Street. Turn left at the light, and make an immediate right onto the service road. Follow the service road to Utopia Parkway and bear right to campus.
From Connecticut (North)
Follow I-95 South to the Bruckner Expressway toward the Throgs Neck Bridge. Cross the bridge to the Clearview Expressway. Take exit 2 from the Clearview and make a right onto Union Turnpike. Make a left onto Utopia Parkway; proceed to main gate (1) and make a right onto campus.
From New Jersey
Take I-95 North or I-80 East to the George Washington Bridge. Cross the bridge and take the Cross Bronx Expressway to I-295 to the Throgs Neck Bridge. Follow directions above from Bronx (Option One).
Parking Rules and Regulations
View the parking program page for more information on:
- How to apply for a permit
- Where to park
- Enforcement and fines
La Guardia Airport
Take the Grand Central Parkway east (toward Long Island). Exit at Utopia Parkway, turn left at the light and left onto the campus (a 15 minute drive).
Take the Van Wyck Expressway to the Main Street/Union Turnpike, exit. Proceed to the third traffic light and make a right onto the Grand Central Parkway service road. Make a left on Utopia Parkway (at the fourth traffic light) and enter the campus (a 15-20 minute drive).
Take train to Kew Gardens/Union Turnpike station. Take Q-46 bus to Union Turnpike and Utopia Parkway.
Take train to 169th Street station. Take Q-30 or Q-31 bus to St. John's University main gate on Utopia Parkway and 82nd Avenue.
I.R.T. Subway, 7 Train
Take train to Main Street, Flushing.
Take Q-17 bus to Utopia Parkway and the Long Island Expressway. Transfer to the Q-30 or Q-31 bus to St. John's University main gate on Utopia Parkway and 82nd Avenue.
Long Island Railroad (L.I.R.R.)
Take L.I.R.R. to Jamaica Station. Take the Q-30 bus to St. John's University main gate on Utopia Parkway and 82nd Avenue.
8th Annual Charles I. Jarowski Symposium
Application of Hot Melt Extrusion Technology in Drug Product Development
Hot melt extrusion has been used in the plastic industry for almost 75 years. However, it is only in the past 10 to 15 years that it has gained wide acceptance in the pharmaceutical industry for the development of drug products and devices. It provides a solvent-free method of preparing solid dispersion of poorly water-soluble drugs, and it is amenable to the development of modified release dosage forms. It has also found special pharmaceutical applications in the preparation of ocular inserts, vaginal rings, implants, devices, etc. The technology has also been used to prepare abuse retardant dosage forms of controlled drug substances. Another related process, melt granulation using twin-screw extruder, has led to the development of high-dose tablets, bilayer tablets, extended release products, co-processed materials, etc. Melt granulation may also help in the development of continuous manufacturing process for solid dosage forms. On the first day of the conference, several major products based on melt extrusion and melt granulation principles have already been marketed.
In this conference, the leading experts on hot melt extrusion representing both industry and academia presented various theoretical, practical and technical aspects of the melt extrusion process. The application of the technology in several different types of pharmaceutical products was discussed. During thhe second day of the conference, the attendees were provided training on preformulation and formulation aspects of drug product development using melt extrusion technology.